1887
Perspective Open Access
Like 0

Abstract

The introduction of point-of-care tests (POCTs) has presented new opportunities for the management of patients presenting to healthcare providers with acute respiratory symptoms. This Perspective article is based on the experiences of national infection teams/those managing acute respiratory infections across the United Kingdom in terms of the challenges and opportunities that this may present for public health. This Perspective article was conceived and written pre-coronavirus disease (COVID-19), however the principles we outline here for influenza can also be translated to COVID-19 and some key points are made throughout the article. The greatest challenge for intergrating POCTs into non-traditional environments is the capture of data and samples for surveillance purposes which provides information for public health action. However, POCTs together with measures outlined in this article, offer a new paradigm for the management and public health surveillance of patients with influenza.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2020.25.44.1900420
2020-11-05
2021-01-22
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2020.25.44.1900420
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/25/44/eurosurv-25-44-5.html?itemId=/content/10.2807/1560-7917.ES.2020.25.44.1900420&mimeType=html&fmt=ahah

References

  1. Public Health England (PHE). Point of care tests for influenza and other respiratory viruses. London: PHE; 27 Nov 2018. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/846008/Point_of_care_tests_for_influenza_and_other_respiratory_viruses.pdf
  2. Merckx J, Wali R, Schiller I, Caya C, Gore GC, Chartrand C, et al. Diagnostic Accuracy of Novel and Traditional Rapid Tests for Influenza Infection Compared With Reverse Transcriptase Polymerase Chain Reaction: A Systematic Review and Meta-analysis. Ann Intern Med. 2017;167(6):394-409.  https://doi.org/10.7326/M17-0848  PMID: 28869986 
  3. Lee JJ, Verbakel JY, Goyder CR, Ananthakumar T, Tan PS, Turner PJ, et al. The Clinical Utility of Point-of-Care Tests for Influenza in Ambulatory Care: A Systematic Review and Meta-analysis. Clin Infect Dis. 2019;69(1):24-33.  https://doi.org/10.1093/cid/ciy837  PMID: 30285232 
  4. Youngs J, Marshall B, Farragher M, Whitney L, Glass S, Pope C, et al. Implementation of influenza point-of-care testing and patient cohorting during a high-incidence season: a retrospective analysis of impact on infection prevention and control and clinical outcomes. J Hosp Infect. 2019;101(3):276-84.  https://doi.org/10.1016/j.jhin.2018.11.010  PMID: 30471317 
  5. Brendish NJ, Malachira AK, Beard KR, Ewings S, Clark TW. Impact of turnaround time on outcome with point-of-care testing for respiratory viruses: a post hoc analysis from a randomised controlled trial. Eur Respir J. 2018;521800555. 13993003.00555-2018
  6. Rogan DT, Kochar MS, Yang S, Quinn JV. Impact of Rapid Molecular Respiratory Virus Testing on Real-Time Decision Making in a Pediatric Emergency Department. J Mol Diagn. 2017;19(3):460-7.  https://doi.org/10.1016/j.jmoldx.2017.01.009  PMID: 28341587 
  7. Klepser DG, Klepser ME, Smith JK, Dering-Anderson AM, Nelson M, Pohren LE. Utilization of influenza and streptococcal pharyngitis point-of-care testing in the community pharmacy practice setting. Res Social Adm Pharm. 2018;14(4):356-9.  https://doi.org/10.1016/j.sapharm.2017.04.012  PMID: 28479019 
  8. You JHS, Tam LP, Lee NLS. Cost-effectiveness of molecular point-of-care testing for influenza viruses in elderly patients at ambulatory care setting. PLoS One. 2017;12(7):e0182091.  https://doi.org/10.1371/journal.pone.0182091  PMID: 28750092 
  9. Evans C, Raza M, Zaidi SK. Influenza point of care testing: a Sheffield Teaching Hospital experience. Royal College of Pathologists The Bulletin.2018; (184):241-3.
  10. National Institute for Health and Care Excellence (NICE). Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza. London: NICE; 24 Sep 2008. Available from: https://www.nice.org.uk/guidance/ta158/resources/oseltamivir-amantadine-review-and-zanamivir-for-the-prophylaxis-of-influenza-pdf-82598321461957
  11. Shengchen D, Gu X, Fan G, Sun R, Wang Y, Yu D, et al. Evaluation of a molecular point-of-care testing for viral and atypical pathogens on intravenous antibiotic duration in hospitalized adults with lower respiratory tract infection: a randomized clinical trial. Clin Microbiol Infect. 2019;25(11):1415-21.  https://doi.org/10.1016/j.cmi.2019.06.012  PMID: 31229593 
  12. Dolk FCK, Pouwels KB, Smith DRM, Robotham JV, Smieszek T. Antibiotics in primary care in England: which antibiotics are prescribed and for which conditions? J Antimicrob Chemother. 2018;73(suppl_2):ii2-10. PMID: 29490062 
  13. Bou-Antoun S, Costelloe C, Honeyford K, Mazidi M, Hayhoe BWJ, Holmes A, et al. Age-related decline in antibiotic prescribing for uncomplicated respiratory tract infections in primary care in England following the introduction of a national financial incentive (the Quality Premium) for health commissioners to reduce use of antibiotics in the community: an interrupted time series analysis. J Antimicrob Chemother. 2018;73(10):2883-92.  https://doi.org/10.1093/jac/dky237  PMID: 29955785 
  14. World Health Organization (WHO). Global Action Plan on Antimicrobial Resistance. Geneva: WHO; 2015. Available from: https://apps.who.int/iris/bitstream/handle/10665/193736/9789241509763_eng.pdf?sequence=1
  15. Department of Health. Department for Environment Food and Rural Affairs. UK Five Year Antimicrobial Resistance Strategy 2013 to 2018. London: Department of Health; 2013. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/244058/20130902_UK_5_year_AMR_strategy.pdf
  16. Shapiro NI, Self WH, Rosen J, Sharp SC, Filbin MR, Hou PC, et al. A prospective, multi-centre US clinical trial to determine accuracy of FebriDx point-of-care testing for acute upper respiratory infections with and without a confirmed fever. Ann Med. 2018;50(5):420-9.  https://doi.org/10.1080/07853890.2018.1474002  PMID: 29775092 
  17. Li-Kim-Moy J, Dastouri F, Rashid H, Khandaker G, Kesson A, McCaskill M, et al. Utility of early influenza diagnosis through point-of-care testing in children presenting to an emergency department. J Paediatr Child Health. 2016;52(4):422-9.  https://doi.org/10.1111/jpc.13092  PMID: 27145506 
  18. Murray JLK, Marques DFP, Cameron RL, Potts A, Bishop J, von Wissmann B, et al. Moving epidemic method (MEM) applied to virology data as a novel real time tool to predict peak in seasonal influenza healthcare utilisation. The Scottish experience of the 2017/18 season to date. Euro Surveill. 2018;23(11):11-8.  https://doi.org/10.2807/1560-7917.ES.2018.23.11.18-00079  PMID: 29560854 
  19. Vega T, Lozano JE, Meerhoff T, Snacken R, Mott J, Ortiz de Lejarazu R, et al. Influenza surveillance in Europe: establishing epidemic thresholds by the moving epidemic method. Influenza Other Respir Viruses. 2013;7(4):546-58.  https://doi.org/10.1111/j.1750-2659.2012.00422.x  PMID: 22897919 
  20. Dickson EM, Marques DFP, Currie S, Little A, Mangin K, Coyne M, et al. The experience of point of care testing for influenza in Scotland in 2017/18 and 2018/19 - no gain without pain. Euro Surveill. 2020;25(44):1900419.  https://doi.org/10.2807/1560-7917.ES.2020.25.44.1900419 
  21. COVID-19 National DiagnOstic Research and Evaluation Platform (CONDOR). A single route to evaluate new diagnostic tests for COVID-19. Oxford: University of Oxforf; 2020. Available from: https://www.condor-platform.org/
  22. Brendish NJ, Mills S, Ewings S, Clark TW. Impact of point-of-care testing for respiratory viruses on antibiotic use in adults with exacerbation of airways disease. J Infect. 2019;79(4):357-62.  https://doi.org/10.1016/j.jinf.2019.06.010  PMID: 31233809 
  23. Brendish NJ, Poole S, Naidu VV, Mansbridge CT, Norton NJ, Wheeler H, et al. Clinical impact of molecular point-of-care testing for suspected COVID-19 in hospital (COV-19POC): a prospective, interventional, non-randomised, controlled study. Lancet Respir Med. 2020; S2213-2600(20)30454-9. PMID: 33038974
/content/10.2807/1560-7917.ES.2020.25.44.1900420
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error